PTEN expression in PTEN-null leukaemic T cell lines leads to reduced proliferation via slowed cell cycle progression

被引:42
作者
Seminario, MC
Precht, P
Wersto, RP
Gorospe, M
Wange, RL
机构
[1] NIA, Cellular & Mol Biol Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA
[2] NIA, Flow Cytometry Lab, IRP, NIH,DHHS, Baltimore, MD 21224 USA
关键词
PTEN; proliferation; cell cycle; apoptosis;
D O I
10.1038/sj.onc.1206872
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The balance of activities between the proto-oncogene phosphoinositide 3-kinase (PI3K) and the tumour suppressor gene PTEN has been shown to affect cellular growth and proliferation, as well as tumorigenesis. Previously, PTEN expression in the PTEN-null Jurkat T cell leukaemia line was shown to cause reduced proliferation without cell cycle arrest. Here, we further these investigations by determining the basis for this phenomenon. By BrdU pulse-chase and cell cycle arrest and release assays, we find that PTEN expression reduced proliferation by slowing progression through all phases of the cell cycle. This was associated with reduced levels of cyclins A, B1 and B2, cdk4, and cdc25A and increased p27(KIP1) expression. Apoptosis played no role in the antiproliferative effect of PTEN, since only marginal increases in the rate of apoptosis were detected upon PTEN expression, and inhibitors of effector caspases did not restore proliferative capacity. Active Akt blocked the antiproliferative effects of PTEN, indicating that PTEN mediates its effects through conventional PI3K-linked signalling pathways. Similar results were obtained from a different PTEN-null leukaemia T cell line, CEM. Together, these results show that PTEN expression in leukaemic T cells leads to reduced proliferation via an apoptosis-independent mechanism involving slower passage through the cell cycle.
引用
收藏
页码:8195 / 8204
页数:10
相关论文
共 47 条
[1]  
AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113
[2]   Early activation of caspases during T lymphocyte stimulation results in selective substrate cleavage in nonapoptotic cells [J].
Alam, A ;
Cohen, LY ;
Aouad, S ;
Sékaly, RP .
JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (12) :1879-1890
[3]   MODFIT - A PHARMACOKINETICS COMPUTER-PROGRAM [J].
ALLEN, GD .
BIOPHARMACEUTICS & DRUG DISPOSITION, 1990, 11 (06) :477-498
[4]   CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells [J].
Appleman, LJ ;
van Puijenbroek, AAFL ;
Shu, KM ;
Nadler, LM ;
Boussiotis, VA .
JOURNAL OF IMMUNOLOGY, 2002, 168 (06) :2729-2736
[5]   Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F [J].
Brennan, P ;
Babbage, JW ;
Burgering, BMT ;
Groner, B ;
Reif, K ;
Cantrell, DA .
IMMUNITY, 1997, 7 (05) :679-689
[6]   New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase AKT pathway [J].
Cantley, LC ;
Neel, BG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (08) :4240-4245
[7]  
Cheyney IW, 1999, CANCER RES, V59, P2318
[8]  
Davies MA, 1999, CANCER RES, V59, P2551
[9]  
DAVIES MA, 2002, CLIN CANCER RES, V8, P1695
[10]   A QUICK AND SIMPLE METHOD FOR THE QUANTITATION OF LACTATE-DEHYDROGENASE RELEASE IN MEASUREMENTS OF CELLULAR CYTO-TOXICITY AND TUMOR NECROSIS FACTOR (TNF) ACTIVITY [J].
DECKER, T ;
LOHMANNMATTHES, ML .
JOURNAL OF IMMUNOLOGICAL METHODS, 1988, 115 (01) :61-69